Income Statement

CONTINEUM THERAPEUTICS, INC.

CTNM

Performance Overview Click any row in the table to add it to this chart

in millions USD

Metric	Dec 31, 2025 2025 FY	Dec 31, 2024 2024 FY
Revenue	-	0.00
Cost of Revenue	-	-
Gross Profit	-	-
Operating Expenses	68.06	50.89
Research & Development	51.52	38.42
Selling, General & Administrative	16.54	12.47
Other Operating Expenses	-	-
Operating Income	-68.06	-50.89
Non-Operating Income	8.08	8.64
Interest Income	8.25	8.91
Interest Expense	-	-
Other Non-Op Income / Expense	-0.17	-0.16
Income Before Tax	-60.14	-42.26
Income Tax Expense	-	0.00
Non-Controlling Interest	-	-
Net Income	-59.98	-42.26

Supplemental Per share data, derived & other items — not part of the income statement

in millions USD unless noted